Neurocrine Biosciences, Inc. $NBIX Shares Bought by Cwm LLC

Cwm LLC boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 150.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,289 shares of the company’s stock after acquiring an additional 15,786 shares during the quarter. Cwm LLC’s holdings in Neurocrine Biosciences were worth $3,304,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its position in shares of Neurocrine Biosciences by 4.2% during the second quarter. IFP Advisors Inc now owns 2,172 shares of the company’s stock worth $273,000 after buying an additional 88 shares during the period. DE Burlo Group Inc. boosted its position in shares of Neurocrine Biosciences by 2.2% during the first quarter. DE Burlo Group Inc. now owns 4,717 shares of the company’s stock worth $522,000 after buying an additional 100 shares during the period. Central Pacific Bank Trust Division boosted its position in shares of Neurocrine Biosciences by 6.2% during the second quarter. Central Pacific Bank Trust Division now owns 1,725 shares of the company’s stock worth $217,000 after buying an additional 100 shares during the period. Nissay Asset Management Corp Japan ADV boosted its position in shares of Neurocrine Biosciences by 0.9% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 12,293 shares of the company’s stock worth $1,360,000 after buying an additional 107 shares during the period. Finally, Sowell Financial Services LLC boosted its position in shares of Neurocrine Biosciences by 2.2% during the second quarter. Sowell Financial Services LLC now owns 4,893 shares of the company’s stock worth $615,000 after buying an additional 107 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $140.09 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $154.61. The stock has a market cap of $13.89 billion, a PE ratio of 41.45, a P/E/G ratio of 0.99 and a beta of 0.21. The stock’s fifty day moving average is $138.65 and its two-hundred day moving average is $125.96.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The company had revenue of $687.50 million for the quarter, compared to analysts’ expectations of $653.09 million. During the same period last year, the firm earned $1.63 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 16.5% on a year-over-year basis. On average, research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the sale, the director owned 514,596 shares in the company, valued at approximately $65,050,080.36. The trade was a 17.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on NBIX. Morgan Stanley raised their price target on Neurocrine Biosciences from $158.00 to $163.00 and gave the stock an “overweight” rating in a research report on Friday, September 5th. Piper Sandler raised their price target on Neurocrine Biosciences from $154.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Royal Bank Of Canada raised their price target on Neurocrine Biosciences from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Wall Street Zen upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 2nd. Finally, Guggenheim lifted their target price on Neurocrine Biosciences from $165.00 to $175.00 and gave the company a “buy” rating in a report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $163.44.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.